Intraperitoneal treatment and dose-intense therapy in ovarian cancer

Annals of Oncology

Volumn 10, Issue SUPPL. 1, 1999, Pages

  Ozols, R F ^a   Gore, M ^b   Trope C ^c   Grenman, S ^d  

^a FOX CHASE CANCER CENTER   (United States)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Autologous bone marrow transplantation; Dose intensity; Intraperitoneal therapy; Ovarian cancer; Peripheral stem cell transplantation

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL;

ADVANCED CANCER; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG MEGADOSE; DRUG PENETRATION; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; OVARY CANCER; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

EID: 0032911528     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0923-7534(20)31486-1     Document Type: Conference Paper

References (33)

1. Markman M. Intraperitoneal therapy of ovarian cancer. Semin Oncol 1998; 25: 356-60.
2. Markman M, Reichman B, Hakes T, et al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: Influence of a prior response to intravenous cisplatin. J Clin Oncol 1991; 9: 1801-5.
3. Howell SB, Zimm S, Markman M, et al. Long term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol 1987; 5: 1607-12.
4. Markman M, Reichman B, Hakes T, et al. Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small volume residual ovarian cancer. J Clin Oncol 1992; 10: 1479-84.
5. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335: 1950-5.
6. McGuire WP, Ozols RF. Chemotherapy of advanced ovarian cancer. Semin Oncol 1998; 25: 340-8.
7. Markman M, Bundy B, Benda J, et al. Randomized phase 3 study of intravenous (IV) cisplatin (CIS)/paclitaxel (PAC) versus moderately high dose IV carboplatin (CARB) followed by IV PAC and intraperitoneal (IP) CIS in optimal residual ovarian cancer (OC): An inter-group trial (GOG, SWOG, ECOG). Proc Am Soc Clin Oncol 1998; 17: 361a, (Abstr).
8. Markman M, Rowinsky E, Hakes T, et al. Phase I trial of intraperitoneal taxol: A Gynecologic Oncology Group study. J Clin Oncol 1992; 10: 1485-91.
9. Markman M, Brady MF, Spirtos NM, et al. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: A Gynecologic Oncology Group study. J Clin Oncol 1998; 16: 2620-4.
10. Levin L, Hryniuk WM. Dose-intensity analysis of chemotherapeutic agents in ovarian cancer. J Clin Oncol 1987; 5: 756-67.
11. Levin L, Simon R, Hryniuk W. Importance of multiagent chemotherapy regimens in ovarian cancer: dose intensity analysis. J Natl Cancer Inst 1993; 85: 1732-42.
12. Enrlick CE, Einhorn L, Stehman FB, et al. Treatment of advanced epithelial ovarian cancer using cisplatin, adriamycin and cytoxan - The Indiana University Experience. Clin Obst Gynaecol 1983; 10: 325-35.
13. Ngan HYS, Choo YC, Cheung M, et al. A randomised study of high-dose versus low-dose cisplatin combined with cyclophosphamide in the treatment of advanced ovarian cancer. Chemotherapy 1989; 35: 221-7.
14. Colombo N, Pittelli MR, Parma G. Cisplatin (P) dose-intensity in advanced ovarian cancer (AOC): A randomized study of conventional dose (DC) vs dose-intense (DI) cisplatin monochemotherapy. Proc Am Soc Clin Oncol 1993; 12: 255 (Abstr).
15. Murphy D, Crowther D, Renninson J, et al. A randomised dose intensity study in ovarian carcinoma comparing chemotherapy given at four week intervals for six cycles with half dose chemotherapy given for twelve cycles. Ann Oncol 1993; 4: 377-83.
16. Bella M, Cocconi G, Lotticci R, et al. Mature results of a prospective randomised trial comparing two different dose-intensity regimens of cisplatin in advanced ovarian carcinoma. Ann Oncol 1994; 5:23, (Suppl 8; Abstr 03).
17. Conte PF, Bruzzone M, Carnino F, et al. High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: A randomized study of the Gruppo Oncologico Nord-Ovest. J Clin Oncol 1996; 14: 351-6.
18. Dittrich C, Obermair A, Kurz C, et al. Prospective randomized trial of cisplatin/carboplatin versus conventional cisplatin/cyclophosphamide in epithelial ovarian cancer: First results of the impact of platinum dose-intensity on patient outcome. Proc Am Soc Clin Oncol 1996; 15: 749, (Abstr).
19. McGuire WP, Hoskins WJ, Bradey MF, et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: A Gynaecologic Oncology Group Study. J Clin Oncol 1995; 13: 1589-99.
20. Jackobsen A, Bertelsen K, Andersen JE, et al. Dose-effect study of carboplatin in ovarian cancer. A Danish Ovarian Cancer Group study. J Clin Oncol 1997; 15: 193-8.
21. Kaye SB, Paul J, Cassidy J, et al. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. J Clin Oncol 1996; 14: 2113-9.
22. Kaye SB, Lewis CR, Paul J, et al. Randomized study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 1992; 340: 329-33.
23. Gore M, Mainwaring P, A'Hem R, et al. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. J Clin Oncol 1998; 16: 2426-34.
24. Grenman S, Rantanen V, Salmi TA. High-dose chemotherapy with autologous stem cell support in advanced ovarian cancer. Ann Med 1996; 28: 151-8.
25. de Vries EGE, Hamilton TC, Lind M, et al. Drug resistance, supportive care and dose intensity. Ann Oncol 1993; 4: S57-62.
26. Stiff PJ, Bayer R, Kerger, C, et al. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: A multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol 1997; 4: 1309-17.
27. Murakami M, Shinozuka T, Kuroshima Y, et al. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of malignant ovarian tumours. Semin Oncol 1994; 21: 29-32.
28. Benedetti-Panici P, Greggi S, Scambia G, et al. Very high-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancer. Eur J Cancer 1995; 12: 1987-91.
29. Fenelly D, Schneider D, Spriggs DR , et al. Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilisation and haematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses. J Clin Oncol 1995; 13: 1160-6.
30. Aghajanian C, Fennelly D, Shapiro F, et al. Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer. J Clin Oncol 1998; 16: 1852-60.
31. Omura GA, Bundy BN, Berek JS, et al. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 1989; 7: 457-65.
32. Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994; 170: 974-80.
33. Schilder RJ, Gallo JM, Johnson SW, et al. Phase I study of multiple cycles of high dose topotecan, carboplatin and paclitaxel with peripheral blood stem cell support. Proc Am Soc Clin Oncol 1998; 17: 75a, (Abstr).